What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

Pipeline Analysis

PUBLISHER: 360iResearch | PRODUCT CODE: 1580918

PUBLISHER: 360iResearch | PRODUCT CODE: 1580918

FASN Inhibitor Market by Drug Type (Natural Product Inhibitors, Peptide Inhibitors, Small Molecule Inhibitors), Route of Administration (Intravenous, Oral), Application, End-User - Global Forecast 2025-2030

PUBLISHED: October 31, 2024

PAGES: 199 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The FASN Inhibitor Market was valued at USD 329.35 million in 2023, expected to reach USD 356.56 million in 2024, and is projected to grow at a CAGR of 8.32%, to USD 576.38 million by 2030.

FASN (Fatty Acid Synthase) inhibitors represent a class of therapeutic agents targeting the enzyme responsible for the synthesis of palmitate, a saturated fatty acid crucial for lipid biosynthesis and energy metabolism. These inhibitors are gaining attention primarily in oncological applications, as cancer cells exhibit heightened lipogenesis, relying on FASN for growth and survival. The growing prevalence of cancer, alongside increasing R&D investments, underscores the necessity for innovative treatments like FASN inhibitors, especially with expanding applications in metabolic diseases and obesity. End-use scope extends across pharmaceutical companies, research institutes, and potentially within the nutraceuticals sector for metabolic health solutions. Key growth factors include the rising incidence of cancer, advancements in biotechnology, and collaboration between academia and industry fostering drug development. Several opportunities are emerging, such as leveraging AI and machine learning for drug discovery, exploring combination therapies to enhance efficacy, and expanding into regional markets with supportive healthcare infrastructure. Nevertheless, the market faces challenges, including high developmental costs, stringent regulatory hurdles, and potential adverse effects that hinder widespread adoption. Intellectual property issues and the limited number of trials demonstrating efficacy in humans also pose significant barriers. Innovation areas involve identifying novel biomarkers for patient stratification, improving delivery methods to enhance bioavailability, and developing next-generation inhibitors with greater specificity. Continuous insight into the competitive landscape and strategic partnerships can propel advancements and market penetration. Understanding patient needs and regulatory compliance will be crucial for navigating this competitive yet promising landscape. By addressing these challenges while harnessing emerging technologies and collaborative frameworks, stakeholders can effectively capitalize on the dynamic nature of the FASN inhibitor market, paving the way for breakthroughs in cancer and metabolic disorders treatment.

KEY MARKET STATISTICS
Base Year [2023]	USD 329.35 million
Estimated Year [2024]	USD 356.56 million
Forecast Year [2030]	USD 576.38 million
CAGR (%)	8.32%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving FASN Inhibitor Market

The FASN Inhibitor Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Rising prevalence of metabolic and oncological disorders
- Supportive regulatory policies for expedited drug approval
- Emerging usage of FASN inhibitors to treat infectious diseases
Market Restraints
- High costs of FASN inhibitors due to need for advanced technology and specialized raw materials
Market Opportunities
- Strategic partnerships and collaborations to enhance research and development processes
- Development of novel drugs and therapies based on FASN inhibitor
Market Challenges
- Limited commercialization and developments in FASN inhibitors

Porter's Five Forces: A Strategic Tool for Navigating the FASN Inhibitor Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the FASN Inhibitor Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the FASN Inhibitor Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the FASN Inhibitor Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the FASN Inhibitor Market

A detailed market share analysis in the FASN Inhibitor Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the FASN Inhibitor Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the FASN Inhibitor Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the FASN Inhibitor Market

A strategic analysis of the FASN Inhibitor Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the FASN Inhibitor Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Abcam Limited, Antipodean Pharmaceuticals, Ascletis Pharma Inc., Bio-Techne Corporation, Boehringer Ingelheim International GmbH, Cayman Chemical Company, Enzo Biochem, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Manus Aktteva Biopharma LLP, MedChemExpress, Merck KGaA, Niksan Pharmaceutical, Pfizer Inc., Sagimet Biosciences, Santa Cruz Biotechnology, Inc., Spansules Pharma, Takeda Pharmaceutical Company Limited, and VWR International by Avantor.

Market Segmentation & Coverage

This research report categorizes the FASN Inhibitor Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Drug Type, market is studied across Natural Product Inhibitors, Peptide Inhibitors, and Small Molecule Inhibitors.
Based on Route of Administration, market is studied across Intravenous and Oral.
Based on Application, market is studied across Cancer Treatment, Infectious Diseases, and Metabolic Disorders.
Based on End-User, market is studied across Academic & Research Institutes and Pharmaceutical Companies.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-6A132FD32B24

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of metabolic and oncological disorders
  - 5.1.1.2. Supportive regulatory policies for expedited drug approval
  - 5.1.1.3. Emerging usage of FASN inhibitors to treat infectious diseases
- 5.1.2. Restraints
  - 5.1.2.1. High costs of FASN inhibitors due to need for advanced technology and specialized raw materials
- 5.1.3. Opportunities
  - 5.1.3.1. Strategic partnerships and collaborations to enhance research and development processes
  - 5.1.3.2. Development of novel drugs and therapies based on FASN inhibitor
- 5.1.4. Challenges
  - 5.1.4.1. Limited commercialization and developments in FASN inhibitors
5.2. Market Segmentation Analysis
- 5.2.1. Drug Type: Growing preferences for peptide inhibitors due to its highly specificity to their targets
- 5.2.2. Application: Growing prevalence of cancer across the globe boost the need for effective FASN inhibitor
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. FASN Inhibitor Market, by Drug Type

6.1. Introduction
6.2. Natural Product Inhibitors
6.3. Peptide Inhibitors
6.4. Small Molecule Inhibitors

7. FASN Inhibitor Market, by Route of Administration

7.1. Introduction
7.2. Intravenous
7.3. Oral

8. FASN Inhibitor Market, by Application

8.1. Introduction
8.2. Cancer Treatment
8.3. Infectious Diseases
8.4. Metabolic Disorders

9. FASN Inhibitor Market, by End-User

9.1. Introduction
9.2. Academic & Research Institutes
9.3. Pharmaceutical Companies

10. Americas FASN Inhibitor Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific FASN Inhibitor Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa FASN Inhibitor Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Sagimet Biosciences Unveils Promising Study Results on FASN Inhibitor and Semaglutide Combination for NASH Treatment
- 13.3.2. Ascletis Pharma Completes Enrollment for Crucial Phase III Trial of ASC40 in Recurrent Glioblastoma Treatment
13.4. Strategy Analysis & Recommendation

Companies Mentioned

1. AbbVie Inc.
2. Abcam Limited
3. Antipodean Pharmaceuticals
4. Ascletis Pharma Inc.
5. Bio-Techne Corporation
6. Boehringer Ingelheim International GmbH
7. Cayman Chemical Company
8. Enzo Biochem, Inc.
9. Gilead Sciences, Inc.
10. GlaxoSmithKline PLC
11. Johnson & Johnson Services, Inc.
12. Manus Aktteva Biopharma LLP
13. MedChemExpress
14. Merck KGaA
15. Niksan Pharmaceutical
16. Pfizer Inc.
17. Sagimet Biosciences
18. Santa Cruz Biotechnology, Inc.
19. Spansules Pharma
20. Takeda Pharmaceutical Company Limited
21. VWR International by Avantor

Product Code: MRR-6A132FD32B24

LIST OF FIGURES

FIGURE 1. FASN INHIBITOR MARKET RESEARCH PROCESS
FIGURE 2. FASN INHIBITOR MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL FASN INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL FASN INHIBITOR MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL FASN INHIBITOR MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL FASN INHIBITOR MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES FASN INHIBITOR MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES FASN INHIBITOR MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. FASN INHIBITOR MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. FASN INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

TABLE 1. FASN INHIBITOR MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL FASN INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL FASN INHIBITOR MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. FASN INHIBITOR MARKET DYNAMICS
TABLE 7. GLOBAL FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL FASN INHIBITOR MARKET SIZE, BY NATURAL PRODUCT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL FASN INHIBITOR MARKET SIZE, BY PEPTIDE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL FASN INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL FASN INHIBITOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL FASN INHIBITOR MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL FASN INHIBITOR MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL FASN INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL FASN INHIBITOR MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL FASN INHIBITOR MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL FASN INHIBITOR MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. CANADA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 35. CANADA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. CANADA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. CANADA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. MEXICO FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 39. MEXICO FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. MEXICO FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. MEXICO FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES FASN INHIBITOR MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52. AUSTRALIA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. CHINA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 57. CHINA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. CHINA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. CHINA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. INDIA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 61. INDIA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. INDIA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 63. INDIA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. INDONESIA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. JAPAN FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 69. JAPAN FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. JAPAN FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. JAPAN FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. MALAYSIA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 76. PHILIPPINES FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. SINGAPORE FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. SOUTH KOREA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. TAIWAN FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 92. THAILAND FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 93. THAILAND FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. THAILAND FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. THAILAND FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. VIETNAM FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA FASN INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 105. DENMARK FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. DENMARK FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. DENMARK FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. DENMARK FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. EGYPT FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 110. EGYPT FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. EGYPT FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. EGYPT FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. FINLAND FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. FINLAND FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. FINLAND FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. FINLAND FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. FRANCE FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 118. FRANCE FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. FRANCE FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. FRANCE FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. GERMANY FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 122. GERMANY FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. GERMANY FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. GERMANY FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. ISRAEL FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. ITALY FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 130. ITALY FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. ITALY FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. ITALY FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. NETHERLANDS FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. NORWAY FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 142. NORWAY FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. NORWAY FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. NORWAY FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. POLAND FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 146. POLAND FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. POLAND FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. POLAND FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. QATAR FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 150. QATAR FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. QATAR FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. QATAR FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. SPAIN FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 166. SPAIN FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. SPAIN FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. SPAIN FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. SWEDEN FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. SWITZERLAND FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 177. TURKEY FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 178. TURKEY FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. TURKEY FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. TURKEY FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM FASN INHIBITOR MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM FASN INHIBITOR MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM FASN INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM FASN INHIBITOR MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. FASN INHIBITOR MARKET SHARE, BY KEY PLAYER, 2023
TABLE 190. FASN INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2023